<DOC>
	<DOC>NCT02362880</DOC>
	<brief_summary>The main purpose of the study is to assess safety of a single dose of FBB followed by PET scan in individuals at risk of genetic Alzheimer's disease.</brief_summary>
	<brief_title>Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Adult children (&gt; 18 yo) of genetic Alzheimer?s disease patients with a known mutation in PSEN1, APP o PSEN2 genes and who are either cognitively normal (CDR=0) or have mild symptoms of cognitive decline (CDR 0.5 or 1) According to the principal investigator, participants must be committed to participate and complete all study procedures. Has signed the Informed Consent Form voluntarily to participate in the study Subjects that are not able to complete the study. Any major disease or history of a major disease, especially hepatobilliar disease (AST /ALT ? 5 x ULN) or advanced renal insufficiency (creatinine ? 2 x ULN) Current or previous history of alcohol abuse or epilepsy Allergic to Florbetaben or any of its constituents Multiple drug allergies and/or previous history of contrast allergy. Pregnancy or breast feeding or planned pregnancy during the study period Any disease or history of disease which, in the opinion of the investigator, can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function) Evidence for any other neurological or psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>